GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –

Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year

– Previously announced agreement to be acquired by Jazz Pharmaceuticals; transaction expected to close in Q2 2021 –

LONDON and CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended December 31, 2020.

“We are very proud of our strong financial performance and operational progress in 2020, as Epidiolex sales increased by more than 70% during the year despite the challenges of COVID-19. We are well positioned to build on our success and continue to deliver strong growth in 2021 in both the U.S. and Europe, where we continue to make progress preparing for several commercial launches that are expected later this year,” said Justin Gover, chief executive officer of GW. “We have commenced our Phase 3 clinical program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission. Beyond nabiximols, we are advancing a diverse and robust neuroscience pipeline with several preclinical and clinical-stage pipeline candidates as part of our commitment to patients and to developing innovative medicines that address significant unmet needs. We have strong momentum and a tremendous opportunity to continue to build on our global cannabinoid leadership position as we prepare to join Jazz Pharmaceuticals and transform the lives of even more patients and families.”


  • Total revenue for the quarter ended December 31, 2020 was $148.2 million compared to $109.1 million for the quarter ended December 31, 2019.
  • Total revenue for the full-year 2020 was $527.2 million, a 69 percent increase compared to $311.3 million for the prior year period.
  • Net loss for the quarter ended December 31, 2020 was $29.1 million compared to net loss of $24.9 million for the quarter ended December 31, 2019.
  • Cash and cash equivalents at December 31, 2020 were $486.8 million.


  • Epidiolex (cannabidiol) progress:
    • Total net product sales of Epidiolex of $144.1 million for the fourth quarter and $510.5 million for the year ended December 31, 2020.
    • U.S. commercial update
      • U.S. Epidiolex net product sales of $128.8 million for the fourth quarter and $467.6 million for the year ended December 31, 2020
      • TSC indication launched with high prescriber awareness and near universal payer coverage
      • Expanded payer coverage
        • More than 110 million lives with no/broad prior authorization (70% increase in 2020)
    • Ex-U.S. commercial update
      • Ex-U.S. Epidyolex Q4 2020 net product sales of $15.3 million and full-year 2020 sales of $42.9 million
      • Continued progress expanding global reach of Epidyolex:
        • Pricing and reimbursement approved in Germany, Finland and Israel
        • Swissmedic approval received for the adjunctive therapy of seizures associated with LGS and DS
        • Launches in France, Spain and Italy expected in H1 2021
      • EMA TSC approval expected H1 2021
    • Strengthening commercial exclusivity
      • Orphan exclusivity in both the U.S. and EU
      • 14 patents listed in Orange Book, 13 of which expire in 2035
        • Patents include formulation and method of use
      • An additional patent has been granted and will be listed in the Orange Book in Q1 2021 and a further patent is expected to be granted and listed in the Orange Book in Q2 2021
      • Epidiolex composition patent application filed

    • Nabiximols development program:
      • MS Spasticity trials underway
        • Phase 3 placebo-controlled spasm frequency study (N=450)
        • Phase 3 placebo-controlled muscle tone study (N=52)
      • MS Spasticity trials due to commence
        • Phase 3 placebo-controlled muscle tone studies:
          • N=190; Expected start: Q2 2021
          • N=36 (nabiximols responders); Expected start: Q2 2021
        • Additional Phase 3 placebo-controlled spasm frequency study (N=200) in nabiximols responders expected start Q2 2021
      • Spinal Cord Injury (SCI) spasticity clinical program
        • First SCI trial underway
          • N=~100 observational clinical discovery study
        • SCI spasticity trials due to commence
          • N=~160 (muscle tone in nabiximols responders); Placebo-controlled parallel group design. Expected start: 2021
          • N=~400 (spasm frequency); Placebo-controlled parallel group design. Expected start: 2021
  • Additional pipeline programs:
    • Schizophrenia (GWP42003)
      • Phase 2b trial now actively recruiting
    • Autism:
      • CBD formulation Phase 2 study expected to commence in Q1 2021
      • CBDV investigator-led 100 patient placebo-controlled trial in autism underway
    • New botanical cannabinoid pipeline product (GW541)
      • Phase 1 trial underway
      • Potential targets within field of neuropsychiatry
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
      • Phase 1b safety study in patients continues to recruit
      • Orphan Drug and Fast Track Designations granted from FDA and EMA
    • Novel cannabinoid molecule synthesis and preclinical development
      • At least one program expected to enter Phase 1 in 2021
      • Several other molecules have demonstrated preclinical efficacy and are advancing towards the clinic
  • On Feb. 3, 2021, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW announced the companies had entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares (subject to limitations on the maximum and minimum number of Jazz ordinary shares issuable per ADS), for a total consideration of $7.2 billion. The transaction is subject to the approval of GW shareholders, sanction by the High Court of Justice of England and Wales and other customary closing conditions, including regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close in the second quarter of 2021.

Conference Call/Earnings Materials

Given the recently announced agreement for GW to be acquired by Jazz Pharmaceuticals, GW will no longer hold conference calls. Earnings materials are available publicly on the Investor Relations page of GW’s website at Questions may be directed to Investor Relations via e-mail at the contact information below.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Forward-Looking Statements
This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals, including, but not limited to, statements related to financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Epidiolex/Epidyolex (cannabidiol) oral solution and nabiximols, and the safety profile and commercial potential of both medicines, the proposed acquisition of GW Pharmaceuticals and the anticipated timing, results and benefits thereof, including the potential for Jazz Pharmaceuticals to accelerate its growth and neuroscience leadership, and for the acquisition to provide long-term growth opportunities to create shareholder value; Jazz Pharmaceuticals’ expected financing for the transaction; and other statements that are not historical facts. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the companies’ current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jazz Pharmaceuticals’ or GW Pharmaceuticals’ control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals’ and GW Pharmaceuticals’ ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory and shareholder approvals, the sanction of the High Court of Justice of England and Wales and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction; risks related to diverting the attention of GW Pharmaceuticals and Jazz Pharmaceuticals management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk of shareholder litigation in connection with the proposed transaction, including resulting expense or delay; the risk that GW Pharmaceuticals’ business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; Jazz Pharmaceuticals’ ability to obtain the expected financing to consummate the acquisition; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; GW Pharmaceuticals’ dependence on the successful commercialization of Epidiolex/Epidyolex and the uncertain market potential of Epidiolex; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that GW Pharmaceuticals may be unable to submit anticipated regulatory filings on the timeframe anticipated, or at all, or that GW Pharmaceuticals may be unable to obtain regulatory approvals of any of its product candidates, including nabiximols and Epidiolex for additional indications, in a timely manner or at all; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Jazz Pharmaceuticals’ ordinary shares or GW Pharmaceuticals’ American depositary shares or ordinary shares; the possibility that, if Jazz Pharmaceuticals does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Jazz Pharmaceuticals’ ordinary shares could decline; potential litigation associated with the possible acquisition; regulatory initiatives and changes in tax laws; market volatility; and other risks and uncertainties affecting Jazz Pharmaceuticals and GW Pharmaceuticals, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ and GW Pharmaceuticals’ Securities and Exchange Commission (SEC) filings and reports, including Jazz Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, GW Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and future filings and reports by either company. In addition, while Jazz Pharmaceuticals and GW Pharmaceuticals expect the COVID-19 pandemic to continue to adversely affect their respective business operations and financial results, the extent of the impact on the combined company’s ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Moreover, other risks and uncertainties of which Jazz Pharmaceuticals or GW Pharmaceuticals are not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events as at such dates, even if they are subsequently made available by Jazz Pharmaceuticals or GW Pharmaceuticals on their respective websites or otherwise. Neither Jazz Pharmaceuticals nor GW Pharmaceuticals undertakes any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.


Scott Giacobello, Chief Financial Officer

760 795 2200 / 

Kristen Cardillo, VP,
Corporate Communications

760.579.6628 / 
Ben Atwell, FTI Consulting+44 (0)203 727 1000 / 

(in thousands, except share data)
  December 31, 
  2020  2019 
Cash and cash equivalents $486,752  $536,933 
Accounts receivable, net  71,168   48,883 
Inventory  129,138   85,528 
Prepaid expenses and other current assets  42,472   28,292 
Total current assets  729,530   699,636 
Property, plant, and equipment, net  143,767   127,765 
Operating lease assets  25,118   24,916 
Intangible assets  5,565    
Goodwill  6,959   6,959 
Deferred tax assets  20,777   18,123 
Other assets  7,795   4,850 
Total assets $939,511  $882,249 
Liabilities and stockholders’ equity        
Accounts payable $21,870  $9,990 
Accrued liabilities  127,849   99,374 
Current tax liabilities  877   437 
Other current liabilities  9,210   7,760 
Total current liabilities  159,806   117,561 
Long-term liabilities:        
Finance lease liabilities  5,454   5,573 
Operating lease liabilities  22,127   21,650 
Other liabilities  11,034   11,431 
Total long-term liabilities  38,615   38,654 
Total liabilities  198,421   156,215 
Commitments and contingencies        
Stockholders’ equity:        
Ordinary shares par value £0.001; 375,196,172 and 371,068,436 shares outstanding as of December 31, 2020 and 2019, respectively  577   570 
Additional paid-in capital  1,690,151   1,632,046 
Accumulated deficit  (896,087)  (837,959)
Accumulated other comprehensive loss  (53,551)  (68,623)
Total stockholders’ equity  741,090   726,034 
Total liabilities and stockholders’ equity $939,511  $882,249 

(in thousands, except per share amounts)
  Three Months Ended
December 31,
  Year Ended
December 31,
  2020  2019  2020  2019 
Product net sales $148,222  $109,019  $526,830  $310,331 
Other revenue     57   375   1,001 
Total revenues  148,222   109,076   527,205   311,332 
Operating expenses                
Cost of product sales  10,419   7,298   37,531   27,199 
Research and development  56,854   43,535   205,396   142,678 
Selling, general and administrative  103,761   78,351   336,043   259,880 
Total operating expenses  171,034   129,184   578,970   429,757 
Loss from operations  (22,812)  (20,108)  (51,765)  (118,425)
Interest income  87   1,818   1,814   8,464 
Interest expense  (271)  (282)  (1,121)  (1,087)
Other income           104,117 
Foreign exchange loss  (3,544)  (5,073)  (3,974)  (2,272)
Loss before income taxes  (26,540)  (23,645)  (55,046)  (9,203)
Income tax expense (benefit)  2,607   1,301   3,082   (184)
Net loss $(29,147) $(24,946) $(58,128) $(9,019)
Net loss per common share, basic and diluted $(0.08) $(0.07) $(0.15) $(0.02)
Weighted average common shares outstanding, basic
and diluted
  376,680   372,447   375,586   371,580 

(in thousands)
  Year Ended
December 31,
  2020  2019 
Cash flows from operating activities        
Net loss $(58,128) $(9,019)
Adjustments to reconcile net loss to net cash used in operating activities:        
Foreign exchange loss  910   2,709 
Stock-based compensation  58,359   48,030 
Depreciation and amortization  12,757   9,240 
Deferred income taxes  (2,654)  (9,698)
Gain from sale of priority review voucher     (104,117)
Other  528   39 
Changes in operating assets and liabilities:        
Accounts receivable, net  (22,104)  (44,623)
Inventory  (39,873)  (51,125)
Prepaid expenses and other current assets  (9,624)  (9,831)
Other assets  3,290   3,888 
Accounts payable  9,862   805 
Current tax liabilities  (3,404)  (963)
Accrued liabilities  24,890   43,110 
Other liabilities  (2,194)  (1,914)
Net cash used in operating activities  (27,385)  (123,469)
Cash flows from investing activities        
Proceeds from sale of priority review voucher     104,117 
Additions to property, plant and equipment  (18,585)  (40,386)
Additions to capitalized software  (3,018)  (2,102)
Additions to intangible assets - licenses  (6,404)   
Proceeds from disposal of property, plant and equipment      
Net cash (used in) provided by investing activities  (28,007)  61,629 
Cash flows from financing activities        
Proceeds from issuance of ordinary shares, Net of issuance costs      
Proceeds from exercise of stock options  1,579   2,878 
Payments in connection with common stock withheld for employee tax obligation  (1,826)   
Payments on finance leases  (299)  (389)
Payments on landlord financing obligation  (583)  (543)
Net cash (used in) provided by financing activities  (1,129)  1,946 
Effect of exchange rate changes on cash  6,340   5,330 
Net decrease in cash and cash equivalents  (50,181)  (54,564)
Cash and cash equivalents at beginning of period  536,933   591,497 
Cash and cash equivalents at end of period $486,752  $536,933